Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-51-56
P. Novikov, M. Brovko, L. Akulkina, V. Nadtocheeva, P. Potapov, S. Moiseev
Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab administration.
{"title":"Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19","authors":"P. Novikov, M. Brovko, L. Akulkina, V. Nadtocheeva, P. Potapov, S. Moiseev","doi":"10.32756/0869-5490-2022-2-51-56","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-51-56","url":null,"abstract":"Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab administration.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73802735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-37-42
B. V. Uvarovskaia, N. N. Shindryaeva, M. Astaeva, M. V. Melnik
To study the features of arterial hypertension (AH) in males age 18 to 27 years.
目的:探讨18 ~ 27岁男性动脉性高血压(AH)的特点。
{"title":"Arterial hypertension in male conscripts","authors":"B. V. Uvarovskaia, N. N. Shindryaeva, M. Astaeva, M. V. Melnik","doi":"10.32756/0869-5490-2022-2-37-42","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-37-42","url":null,"abstract":"To study the features of arterial hypertension (AH) in males age 18 to 27 years.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75238293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-20-26
V. Nadtocheeva, N. Bulanov, L. Akulkina, T. Berzegova, A. Budko, M. Kalashnikov, A. Moiseev, N. Tairova, E. Tao, G. Tverdokhlebov, E. Filatova, G. Chuchin, N. Shakhgildyan, A. Schepalina, A. Suvorov, A. Kuchieva, M. Vasilyeva, P. Novikov, Y. Sorokin, V. Sholomova, M. Brovko, S. Moiseev
To evaluate the impact of previous vaccination with Gam-COVID-Vac on all-cause mortality in hospitalized adult patients with breakthrough COVID-19.
评价既往接种Gam-COVID-Vac疫苗对突破性COVID-19住院成人患者全因死亡率的影响。
{"title":"Outcomes of breakthrough COVID-19 in hospitalized adult patients vaccinated with Gam-COVID-Vac (Sputnik V)","authors":"V. Nadtocheeva, N. Bulanov, L. Akulkina, T. Berzegova, A. Budko, M. Kalashnikov, A. Moiseev, N. Tairova, E. Tao, G. Tverdokhlebov, E. Filatova, G. Chuchin, N. Shakhgildyan, A. Schepalina, A. Suvorov, A. Kuchieva, M. Vasilyeva, P. Novikov, Y. Sorokin, V. Sholomova, M. Brovko, S. Moiseev","doi":"10.32756/0869-5490-2022-2-20-26","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-20-26","url":null,"abstract":"To evaluate the impact of previous vaccination with Gam-COVID-Vac on all-cause mortality in hospitalized adult patients with breakthrough COVID-19.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"96 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78344268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-32-36
A. Alekseeva, O. P. Alekseeva, S. V. Krishtopenko
To determine the effective doses of prednisone for induction of remission in patients with ulcerative colitis (UC) and Crohn's disease (CD) based on the “dose-effect” relationship.
基于“剂量-效应”关系，确定强的松诱导溃疡性结肠炎(UC)和克罗恩病(CD)患者缓解的有效剂量。
{"title":"Constructing the function of prednisone efficacy for the treatment of inflammatory bowel diseases based on a clinical model","authors":"A. Alekseeva, O. P. Alekseeva, S. V. Krishtopenko","doi":"10.32756/0869-5490-2022-2-32-36","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-32-36","url":null,"abstract":"To determine the effective doses of prednisone for induction of remission in patients with ulcerative colitis (UC) and Crohn's disease (CD) based on the “dose-effect” relationship.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86737066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-76-80
A. B. Sumarokov, M. Ezhov
Statin-induced necrotizing autoimmune myopathy (SINAM) is an exceptionally rare complication of statin therapy. SINAM belongs to the group of idiopathic inflammatory myopathies and is characterized by muscle cell necrosis and regeneration leading to muscle atrophy. Prominent lymphocytic infiltrates in muscle tissue are absent. Progressive muscle weakness in upper and lower extremities is the main clinical manifestation of SINAM. Autoimmune mechanism of pathogenesis explain the absense of therapeutic effect of statin discontinuation and the risk of relapses. Diagnosis of SINAM can be established by clinical and serologic data, muscle biopsy and the results on noninvasive methods (MRI, ultrasound). Early initiation of immunosuppressive treatment is essential to achieve the cure of SINAM.
{"title":"Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy","authors":"A. B. Sumarokov, M. Ezhov","doi":"10.32756/0869-5490-2022-2-76-80","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-76-80","url":null,"abstract":"Statin-induced necrotizing autoimmune myopathy (SINAM) is an exceptionally rare complication of statin therapy. SINAM belongs to the group of idiopathic inflammatory myopathies and is characterized by muscle cell necrosis and regeneration leading to muscle atrophy. Prominent lymphocytic infiltrates in muscle tissue are absent. Progressive muscle weakness in upper and lower extremities is the main clinical manifestation of SINAM. Autoimmune mechanism of pathogenesis explain the absense of therapeutic effect of statin discontinuation and the risk of relapses. Diagnosis of SINAM can be established by clinical and serologic data, muscle biopsy and the results on noninvasive methods (MRI, ultrasound). Early initiation of immunosuppressive treatment is essential to achieve the cure of SINAM.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80138625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-14-19
N. Titova
Tolperisone is a centrally acting muscle relaxant that shows analgesic activity and can be used alone or in combination with NSAIDs for the treatment of nonspecific back pain. Compared with other muscle relaxants tolperison has better safety profile and very low sedative activity. New extendedrelease form of tolperisone (Midocalm Long 450 mg) has optimized pharmacokinetic properties, which enable stable therapeutic blood concetrantion of active substance over 24 hours. Once-daily administration of prolonged acting drug improves adherence to treatment.
{"title":"Tolperisone for the treatment of low back pain","authors":"N. Titova","doi":"10.32756/0869-5490-2022-2-14-19","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-14-19","url":null,"abstract":"Tolperisone is a centrally acting muscle relaxant that shows analgesic activity and can be used alone or in combination with NSAIDs for the treatment of nonspecific back pain. Compared with other muscle relaxants tolperison has better safety profile and very low sedative activity. New extendedrelease form of tolperisone (Midocalm Long 450 mg) has optimized pharmacokinetic properties, which enable stable therapeutic blood concetrantion of active substance over 24 hours. Once-daily administration of prolonged acting drug improves adherence to treatment.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83828130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-43-50.
Y. Korotchaeva, N. Kozlovskaya, K. Demyanova, M. Alexeeva, A. Skvortsov, S. Moiseev
Atypical hemolytic-uremic syndrome (aHUS) is a rare disease caused by uncontrolled activation of the alternative complement pathway and characterized by acute kidney injury, thrombocytopenia, and microangiopathic hemolytic anemia. Up to one third of aHUS patients present with extrarenal manifestations including central nervous system, lung, liver, and gastrointestinal tract involvement. Identified triggers of aHUS include various complement activating disorfers, e.g. complicated pregnancy. Eculizumab, the terminal complement C5 inhibitor, is targeted treatment approved for patients with aHUS. The authors present two cases of aHUS and review its clinical presentation, diagnosis and treatment.
{"title":"Atypical hemolytic-uremic syndrome: clinical presentation, diagnosis and treatment","authors":"Y. Korotchaeva, N. Kozlovskaya, K. Demyanova, M. Alexeeva, A. Skvortsov, S. Moiseev","doi":"10.32756/0869-5490-2022-2-43-50.","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-43-50.","url":null,"abstract":"Atypical hemolytic-uremic syndrome (aHUS) is a rare disease caused by uncontrolled activation of the alternative complement pathway and characterized by acute kidney injury, thrombocytopenia, and microangiopathic hemolytic anemia. Up to one third of aHUS patients present with extrarenal manifestations including central nervous system, lung, liver, and gastrointestinal tract involvement. Identified triggers of aHUS include various complement activating disorfers, e.g. complicated pregnancy. Eculizumab, the terminal complement C5 inhibitor, is targeted treatment approved for patients with aHUS. The authors present two cases of aHUS and review its clinical presentation, diagnosis and treatment.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73357139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.32756/0869-5490-2022-2-63-68
O. Suprun, A. Bagriy, E. Mykhailichenko, M. Krivushcheva
An article reviews the use of glucagon-like peptide-1 (GLP-1) receptor agonists for treatment of patients with type 2 diabetes mellitus associated with high cardiovascular risk, chronic heart failure with low left ventricular ejection fraction and diabetic nephropathy. The authors discuss the mechanisms of action of GLP-1 receptor agonists, their main advantages (significant hypoglycemic effect, organoprotection and improved cardiovascular and renal outcomes) and dosedependent side effects.
{"title":"Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus","authors":"O. Suprun, A. Bagriy, E. Mykhailichenko, M. Krivushcheva","doi":"10.32756/0869-5490-2022-2-63-68","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-63-68","url":null,"abstract":"An article reviews the use of glucagon-like peptide-1 (GLP-1) receptor agonists for treatment of patients with type 2 diabetes mellitus associated with high cardiovascular risk, chronic heart failure with low left ventricular ejection fraction and diabetic nephropathy. The authors discuss the mechanisms of action of GLP-1 receptor agonists, their main advantages (significant hypoglycemic effect, organoprotection and improved cardiovascular and renal outcomes) and dosedependent side effects.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90605300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-13DOI: 10.32756/0869-5490-2021-4-44-51
A. Pereverzev, O. Ostroumova
Any drug can potentially cause adverse drug reactions (ADRs), including serious and fatal. Some of them are caused by interactions with food, in particular, fruit and berry juices. Juices have a complex chemical composition and each of the chemicals can interact with drugs. Grapefruit juice is one of the most popular and well-studed in terms of potential drug interactions juices. Grapefruit juice is an inhibitor of CYP3A enzymes in the intestine involved in the presystemic metabolism of drug substrates. Therefore, it can increase their absorption. Apple juice at a concentration of 5% significantly reduces the activity of OATP, but not the activity of P-glycoprotein, which, for example, leads to a decrease in AUC and Cmax of fexofenadine to 30- 40% relative to the concentration of fexofenadine in patients drinking only water. Taking 200 ml of grape juice can reduce the concentration of phenacetin in blood plasma and increase the ratio of AUC of paracetamol to phenacetin due to the induction of CYP1A2 activity by grape juice flavonoids or by reducing the rate of absorption of phenacetin. To prevent ADRs, it is recommended to take drugs with water and and not consume simultaneously juices that are known to interact with drugs.
{"title":"Potential clinically significant drug interactions of drugs with fruit and berry juices","authors":"A. Pereverzev, O. Ostroumova","doi":"10.32756/0869-5490-2021-4-44-51","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-4-44-51","url":null,"abstract":"Any drug can potentially cause adverse drug reactions (ADRs), including serious and fatal. Some of them are caused by interactions with food, in particular, fruit and berry juices. Juices have a complex chemical composition and each of the chemicals can interact with drugs. Grapefruit juice is one of the most popular and well-studed in terms of potential drug interactions juices. Grapefruit juice is an inhibitor of CYP3A enzymes in the intestine involved in the presystemic metabolism of drug substrates. Therefore, it can increase their absorption. Apple juice at a concentration of 5% significantly reduces the activity of OATP, but not the activity of P-glycoprotein, which, for example, leads to a decrease in AUC and Cmax of fexofenadine to 30- 40% relative to the concentration of fexofenadine in patients drinking only water. Taking 200 ml of grape juice can reduce the concentration of phenacetin in blood plasma and increase the ratio of AUC of paracetamol to phenacetin due to the induction of CYP1A2 activity by grape juice flavonoids or by reducing the rate of absorption of phenacetin. To prevent ADRs, it is recommended to take drugs with water and and not consume simultaneously juices that are known to interact with drugs.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73664238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-13DOI: 10.32756/0869-5490-2021-4-62-70
S. Moiseev, P. Novikov, S. Gulyaev, E. Kuznetsova, T. Shevtsova, I. Shafieva, O. Bugrova
Ankylosing spondilitis (AS) is a relatively common disease mainly affecting young males and presenting with chronic inflammation of the spine and the sacroiliac joints. AS is one of the forms of axial spondyloarthritis (SpA). Diagnosis of AS is usually delayed on average by 8-10 years from the first symptoms. SpA should be considered both in males and females who present with chronic low back pain starting before the age of 45 years and at least one additional factor (inflammatory back pain, HLA-B27, sacroileitis, peripheral arthritis, enthesitis, dactylitis, psoriasis, uveitis, inflammatory bowel disease, family history for SpA, elevated ESR and/or C-reactive protein, and good response to NSAIDs). Such patients should be referred to rheumatologist. MRI improves early diagnosis of AS since it detects inflammatory changes, which precede structural damage of the sacroiliac joints (nonradiographic SpA). Physical exercises and NSAIDs are the first-line treatment for AS, whereas TNF and interleukin-17 inhibitors are widely used as a second-line therapy. Upadacitinib is the first JAK-inhibitor that was approved for the treatment of active AS in adult patients who have responded inadequately to conventional therapy. The authors discuss clinical cases demonstrating efficacy of upadacinitib in patients with AS.
{"title":"Ankylosing spondylitis: diagnostic challenges and efficacy of upadacitinib","authors":"S. Moiseev, P. Novikov, S. Gulyaev, E. Kuznetsova, T. Shevtsova, I. Shafieva, O. Bugrova","doi":"10.32756/0869-5490-2021-4-62-70","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-4-62-70","url":null,"abstract":"Ankylosing spondilitis (AS) is a relatively common disease mainly affecting young males and presenting with chronic inflammation of the spine and the sacroiliac joints. AS is one of the forms of axial spondyloarthritis (SpA). Diagnosis of AS is usually delayed on average by 8-10 years from the first symptoms. SpA should be considered both in males and females who present with chronic low back pain starting before the age of 45 years and at least one additional factor (inflammatory back pain, HLA-B27, sacroileitis, peripheral arthritis, enthesitis, dactylitis, psoriasis, uveitis, inflammatory bowel disease, family history for SpA, elevated ESR and/or C-reactive protein, and good response to NSAIDs). Such patients should be referred to rheumatologist. MRI improves early diagnosis of AS since it detects inflammatory changes, which precede structural damage of the sacroiliac joints (nonradiographic SpA). Physical exercises and NSAIDs are the first-line treatment for AS, whereas TNF and interleukin-17 inhibitors are widely used as a second-line therapy. Upadacitinib is the first JAK-inhibitor that was approved for the treatment of active AS in adult patients who have responded inadequately to conventional therapy. The authors discuss clinical cases demonstrating efficacy of upadacinitib in patients with AS.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89699400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：